- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT01162395
Open Label Prostate Cancer Study
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD3514 in Patients With Metastatic Castration-Resistant Prostate Cancer.
Visão geral do estudo
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Oregon
-
Portland, Oregon, Estados Unidos
- Research Site
-
-
-
-
-
Amsterdam, Holanda
- Research Site
-
-
-
-
-
Glasgow, Reino Unido
- Research Site
-
Manchester, Reino Unido
- Research Site
-
Surrey, Reino Unido
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Males aged 20 years or older.
- Histologically or Cytologically proven diagnosis of prostate cancer for which no standard therapy is currently considered appropriate.
- Documented evidence of metastatic prostate cancer
- Presence of progressive disease defined as one or more:
- Biochemical progression of the prostate cancer
- Progression as defined by Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 guidelines
- Two or more new metastatic bone lesions from bone scans from a previous assessment
- Serum testosterone concentration less or equals 50 ng/dL
- World Health Organization (WHO) performance status 0 to 1 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks.
- Sexually active males should be willing to use condoms
- For inclusion in the AZD3514 administered in combination with abiraterone acetate cohort(s), patients must:
- Have received prior chemotherapy containing or based on docetaxel
- Not have received prior treatment with abiraterone acetate, MDV3100, TAK700, TOK001 or other similar therapies which target the AR axis or with selective AR down-regulator-like properties
For inclusion in the AZD3514 administered in combination with abiraterone acetate in patients who are currently receiving abiraterone acetate cohort(s), patients must:
- Have been stable on abiraterone acetate abiraterone acetate for ≥ 4 months (i.e. stable PSA values) and have achieved ≥ 50% reduction in PSA while being treated with abiraterone acetate
- Have evidence of biochemical progression (PSA) of the prostate cancer, as defined in inclusion number 5 (except for the withdrawal of abiraterone acetate as an anti-androgen therapy)
For inclusion in the paired (same lesion) tumour biopsy research, patients must:
- Provide informed consent for paired tumour biopsy sampling
- Have bone or soft tissue lesions that are suitable for paired biopsy sampling
Exclusion Criteria:
- Any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAEv4) grade 1 except for alopecia or toxicities related to the use of gonadotropin-releasing hormone agonists
- Medically important spinal cord compression or brain metastases
- Medically important evidence of severe or uncontrolled systemic disease
- History of hypersensitivity to active or inactive excipients of AZD3514 or drugs with a similar chemical structure or class to AZD3514
- Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of AZD3514
- Inadequate bone marrow reserve or organ function
- Any medically important factors identified from electrocardiogram (ECG) measurements
- Concurrent or recent treatment with certain medications or medical procedures
The following criteria exclude patients from entering the AZD3514 administered in combination with abiraterone acetate cohort(s):
- As judged by the investigator, any evidence of severe or uncontrolled systemic diseases or conditions, including adrenocortical insufficiency or a history of cardiovascular disease including heart failure (currently there are no randomized data for the use of abiraterone acetate in patients with LVEF < 50% or NYHA Class III or IV heart failure), which would make it undesirable for the patient to participate in the trial. See the full local prescribing information for abiraterone acetate for more detail
- Child-Pugh class B and C hepatic impairment
- If unable to fast for ≥ 2 hours prior to taking a dose to ≥ 1 hour post dose
- Received abiraterone acetate treatment previously
- Known hypersensitivity to components of prednisone or prednisolone
- Any systemic fungal infections
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: A
Ascending doses of AZD3514 administered orally to patients to define the maximum tolerated dose (MTD)
|
Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
To investigate the safety and tolerability of AZD3514 when given orally to patients with CRPC.
Prazo: At every visit.
|
At every visit.
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
To define the MTD, if possible, a lower biologically-effective dose(s) or maximum feasible dose (if decided by the Safety Review Committee (SRC) and AstraZeneca).
Prazo: After each Cohort.
|
After each Cohort.
|
|
To characterise the PK of AZD3514 after a single oral dose and at steady state after multiple oral doses.
Prazo: After each Cohort.
|
After each Cohort.
|
|
To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).
Prazo: Visits 1, 4, 6, 7, 9, 10, follow-up visits, discontinuation visit
|
Visits 1, 4, 6, 7, 9, 10, follow-up visits, discontinuation visit
|
|
To obtain a preliminary assessment of the anti-tumour activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate by evaluation of counts of Circulating Tumour Cells (CTCs).
Prazo: Visits 1, 6, 8, 9, 10, follow-up visits, discontinuation visit
|
Visits 1, 6, 8, 9, 10, follow-up visits, discontinuation visit
|
|
To obtain an assessment of the activity of AZD3514 as monotherapy and/or in combination with abiraterone acetate on the circulating levels of prostate-specific antigen (PSA).
Prazo: Visits 1, 10, follow-up visits, discontinuation visit
|
Visits 1, 10, follow-up visits, discontinuation visit
|
|
To investigate safety, tolerability, MTD (and/or biologically-effective dose(s) or maximum feasible dose) and PK of AZD3514 and abiraterone when administered in combination, in patients who have not received prior treatment with abiraterone acetate
Prazo: At every visit
|
At every visit
|
|
To compare the PK of AZD3514 monotherapy in patients who have been fed or fasted before the administration of study treatment
Prazo: At visits 2 and 4
|
At visits 2 and 4
|
|
To investigate the effect of AZD3514 on biomarkers of AR expression in paired pre- and post-dose tumour biopsies.
Prazo: July 2012 - Feb 2013
|
July 2012 - Feb 2013
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Glen Clack, MD, AstraZeneca
- Investigador principal: Tony Elliott, MD, The Christie Hospital
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- D3760C00001
- 2010-020232-19 (Número EudraCT)
- IND 111707
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .